Availability and Approval

Retatrutide is not currently available for prescription or purchase. Its pivotal Phase 3 trials have all reported, and no application has been filed yet. Lilly says it plans to file for approval no later than the first quarter of 2027. On October 2, 2026 the FDA ruled that the application must be a New Drug Application (NDA); Lilly disputes that in court and has not said which pathway it will use. (In July 2026 Lilly had said it planned a Biologics License Application.) On our estimate, an FDA decision could come in late 2027 with priority review, or around the first quarter of 2028 with standard review.

The main legitimate way to receive retatrutide is participation in an authorized clinical trial. Since August 2026 there is also a narrow expanded access program (NCT07629401) for adults with a BMI of 35 or higher despite maximal approved therapy and two or more serious obesity-related complications, which a treating physician must request from Eli Lilly. The drug is not approved for prescription, and purchasing it outside of a clinical trial setting is not sanctioned by regulatory authorities. We strongly advise against obtaining any investigational compound through unregulated channels.

In all clinical trials to date, retatrutide has been administered as a once-weekly subcutaneous injection. If approved, it is expected to be available initially as an injectable formulation. Whether an oral formulation might be developed in the future is unknown and would require separate clinical development.

Pricing has not been determined, as retatrutide has not been approved for marketing. For context, other incretin-based obesity medications carry US list prices above $1,000 per month (Wegovy's was $1,349 as of February 2026), though what patients pay varies widely. Self-pay prices are lower: as of October 2026, LillyDirect sells Zepbound for $299 to $449 a month depending on dose, and the Foundayo pill for $149 to $349. Retatrutide pricing will depend on its approved indications, competitive positioning, insurance coverage decisions, and Eli Lilly's pricing strategy.

Insurance coverage decisions cannot be predicted at this time. Coverage for obesity medications has historically been limited, though it has been expanding in recent years as the medical community increasingly recognizes obesity as a chronic disease requiring pharmacological treatment. Coverage will depend on the approved indications, individual insurance plans, and payer policies at the time of potential approval.

If retatrutide receives FDA approval, Eli Lilly would be expected to pursue regulatory submissions in other major markets, including the European Union (through the EMA), Japan, Canada, Australia, and other countries. International approval timelines typically lag behind U.S. approval by 6-18 months, depending on the regulatory agency and submission timing.